Bank of America issues 'buy' rating on Parabilis Medicines stock
2 reports, 1 independent
Updated Oct 19
Gone quiet
- Reports
- 2
- Developments
- 2
- Repetition
- 0%
New informationRepeats or wire copies
AI-generated briefing. Brind wrote this from the reports listed below and has updated it as the story developed. It can be wrong. Each section says how much you can rely on it, and the sources are linked so you can check.
What happened
Bank of America issued a 'buy' rating and a $45.00 target price for Parabilis Medicines on October 16, 2026. On the same day, Parabilis Medicines shares traded at a new 52-week low, reaching $24.24. The company currently has a market capitalization of $3.03 billion.
From themarketsdaily.com
Why it matters
The rating change by Bank of America adds to a recent trend of analyst activity regarding Parabilis Medicines. The company currently holds an average rating of 'Moderate Buy' with an average target price of $41.67, according to market reports.
From themarketsdaily.com
Who's involved
- Bank of AmericaIssued a 'buy' rating and a $45.00 target price on Parabilis Medicines stock.
How it developed
Newest first. Tap a step to see who reported it.Leerink Partners and MarketBeat added coverage and consensus ratings to the Parabilis Medicines story.1 source
Bank of America issues a buy rating for Parabilis Medicines.1 source
Keep exploring
The entities involved
-
Bank of America
American multinational banking and financial services corporation
Related events
- Bank of America set a buy rating and price target for Penguin Solutions on October 23, 2026.
- Bank of America updated its price objective and rating, while Citigroup reissued a neutral rating on Biogen shares.
- HSBC retained a Buy rating with a cut target, while Bank of America revised targets and Motilal Oswal maintained a Buy rating for various stocks.
- Bank of America, Benchmark, Benzinga, and MarketBeat provided various stock ratings and updates for Skyworks Solutions.
- Bank of America, Citigroup, and Royal Bank of Canada issued rating upgrades and price target increases for International Paper.